Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study

Wenbo Guo; Jian Gao; Wenquan Zhuang; Zhiqiang Wu; Bin Li; Song Chen

doi:10.1002/jgh3.12285

Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study

JGH Open. 2019 Dec 13;4(3):477-483. doi: 10.1002/jgh3.12285. eCollection 2020 Jun.

Authors

Wenbo Guo¹, Jian Gao², Wenquan Zhuang¹, Zhiqiang Wu¹, Bin Li³, Song Chen¹

Affiliations

¹ Department of Interventional Radiology The First Affiliated Hospital of Sun Yat-Sen University Guangzhou Guangdong Province China.
² Department of Interventional Radiology Baoan District People's Hospital of Shenzhen Shenzhen Guangdong Province China.
³ Clinical Research Unit The First Affiliated Hospital of Sun Yat-Sen University Guangzhou Guangdong Province China.

Abstract

Purpose: The aim of this study was to assess the effectiveness and safety of hepatic arterial infusion chemotherapy (HAIC) using the FOLFOX regimen combined with transarterial embolization (TAE + HAIC) in patients with unresectable hepatocellular carcinoma (HCC).

Methods: Unresectable HCC patients treated with TAE + HAIC and conventional transcatheter arterial chemoembolization (TACE), respectively, between January 2015 and October 2016 in China were retrospectively assessed. The primary outcome was progression-free survival (PFS), while secondary outcomes included the objective response rate (ORR), the disease control rate (DCR), and main complications. Propensity score matching (PSM) was estimated by multiple logistic regression using caliper matching (caliper 0.2). A Cox proportional hazards model was used to identify those factors shown to be associated with PFS.

Results: A total of 113 patients were analyzed, with 41 and 72 receiving TAE + HAIC and TACE, respectively. After PSM, 35 pairs of patients were assessed. The median PFS was 7.93 months (95% confidence interval [CI], 4.44-11.42) for the TAE + HAIC group, which was higher compared with 2.60 months (95% CI, 0.93-4.27, P = 0.003) for TACE. The subgroup with Barcelona clinic liver cancer (BCLC) stage C obtained more PFS benefit from TAE + HAIC (P = 0.002). ORRs in the TAE + HAIC and TACE groups were 37.14% (13/35) and 20.00% (7/35, P = 0.112), respectively; DCRs were 88.57% (31/35) and 60.00% (21/35, P = 0.006), respectively. Abundant blood supply (hazard ratio [HR] =0.327, 95% CI 0.173-0.615, P < 0.001) and TAE + HAIC (HR = 0.332, 95% CI 0.177-0.621, P < 0.001) were associated with longer PFS in multivariate analysis.

Conclusions: Compared with conventional TACE, TAE + HAIC provides more PFS benefits to patients with unresectable HCC, especially in those with BCLC stage C.

Keywords: hepatic arterial infusion chemotherapy; objective response rate; progression‐free survival; retrospective analysis; transarterial chemoembolization; unresectable hepatocellular carcinoma.